Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 4 10 versus TRIAVIL 4 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 4 10 versus TRIAVIL 4 25.
TRIAVIL 4-10 vs TRIAVIL 4-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 4-10 contains perphenazine, a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the limbic system, basal ganglia, and hypothalamus, and amitriptyline, a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake.
TRIAVIL (amitriptyline/perphenazine) combines a tricyclic antidepressant (amitriptyline) that inhibits reuptake of norepinephrine and serotonin, and a phenothiazine antipsychotic (perphenazine) that blocks dopamine D2 receptors, serotonin 5-HT2 receptors, and alpha-adrenergic receptors, with additional anticholinergic, antihistaminergic, and antiemetic properties.
1 tablet (perphenazine 4 mg / amitriptyline 10 mg) orally 3 times daily, maximum 8 tablets daily.
One tablet (perphenazine 4 mg / amitriptyline 25 mg) orally 3 to 4 times daily. Maximum: 8 tablets daily.
None Documented
None Documented
Amitriptyline: 10-28 hours (mean 21 hours); perphenazine: 8-12 hours (mean 10 hours). Clinically, steady-state achieved in 3-5 days for amitriptyline, 2-3 days for perphenazine.
Amitriptyline: 13–36 hours (mean ~21 hours); perphenazine: 8–21 hours (mean ~12 hours); steady-state achieved in 3–10 days.
Primarily renal (about 50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary elimination).
Renal: ~70% as metabolites (including amitriptyline and perphenazine metabolites) and <5% unchanged; fecal: ~30% via bile; enterohepatic recirculation occurs.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination